Elicio reports Phase 1 data for ELI-002: 84% T cell response, 16.3-month median RFS

Elicio Therapeutics, Inc.

AMPLIFY-201 data published in Nature Medicine in 25 patients (20 pancreatic, 5 colorectal) with minimal residual mKRAS disease.
ELI-002 induced direct ex vivo mKRAS-specific T cell responses in 84% of patients; 59% both CD4+ and CD8+.
84% of patients had tumor biomarker reduction; 24% achieved complete biomarker clearance.
Median relapse-free survival was 16.33 months; high T cell responders had 86% reduction in risk of progression or death.
Phase 2 monotherapy trial in pancreatic ductal adenocarcinoma planned to start early 2024; no safety concerns identified.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.